Secoisolariciresinol Diglucoside Exerts Anti-Inflammatory and Antiapoptotic Effects through Inhibiting the Akt/IκB/NF-κB Pathway on Human Umbilical Vein Endothelial Cells
The effect of SDG on HUVEC viability reduces the angiogenic capacity of HUVECs. (a, b) HUVECs are treated with SDG in graded concentrations at lower doses (0, 50, 100, 250, 500, 750, or 1000 nM) and at higher doses (1, 5, 10, 20, 40, 80, and 160 μM); then, cell viability was measured by CCK-8 assay. Compared to the 0 μM or 1 μM group, represents . (c, d) SDG (10 μM) reduces the angiogenic capacity of HUVECs. Error bars represent . represents . All experiments were performed in triplicate. LPS: lipopolysaccharide; SDG: secoisolariciresinol diglucoside.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.